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IN a previous communication Sahasrabudhe (1958) put forth evidence in
support of existence of a chemical competition between nucleic acid and py-ridine
nucleotide syntheses for the appropriation of a common precursor, adenine. In
a rapidly growing malignant tissue, adenine was shown to be appropriated for
nucleic acid synthesis and very little was left forincorporation inpyridine nucleo-
tides (Narurkar, Kumta and Sahasrabudhe, 1957). It was further show-n that the
pyridine nucleotide levels were invariably lowered in presence of rapid nucleic
acid synthesis irrespective of whether it (the nucleic acid synthesis) was of neo-
plastic or non-neoplastic origin (Jedeikin, Thomas and Weinhouse, 1956 ; Kotnis,
Narurkar and Sahasrabudhe, 1959). Pyridine nucleotides have an important
role in the hydrogen transport system and thus indirectly participate in the
production ofenergy, via thetricarboxylic acid cycle. In view ofthis it was sug-
gested that low levels of pyridine nucleotides automatically slow down all the
synthetic and proliferative activities by controlling the energy production.
Based on these ideas, a biological feed-back mechanism was postulated for the
regulation of normal growth processes (Sahasrabudhe, 1958). In'tumour tissue
however, this feed-back-mechanism seems to breakdown; the tumourapparently
is able to obtain an unhmited supply of energy to maintain its rapid nucleic acid
synthesis. A search for an alternate pathway capable of producing energy
independent of the proposed feed-back-mechanism revealed that hexose-mono-
phosphate pathway (HMP) has the requisite potentiality of not only producing
energy (though notyetdefinitelyestablished) but also yieldingribose-5-phosphate
which is the starting material for the biosynthesis of purines. In the light of
this thereportedpreponderance of HMPpathway in tumourtissueacquiresgreater
significance (Kit, 1956; Kit and Graham, 1956; van Vals, Bosch and Emmelot,
1956). Interference of HMP pathway, it was thought, would inhibit the tumour
growth by curtailing the supply ofenergy andribose-5-phosphate. This has been
attempted by preparing anti-metabolites against some suitable intermediates of
the HMP pathway.
Anidealchemotherapeutic substancehasto haveprefere'ntial action on tumours
only, with no or minimuni action on the host tissues. It was this consideration
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bolites of glucose-6-phosphate and fructose-6-phosphate (Sahasrabudhe, 1958).
These two intermediates are common for both the Embden-Meyerhof (EM) and
HMP pathways, and hence the antimetabolites of these would interfere with the
HMP and also the EM pathway and thus may prove harmful to the normal host
tissue. Antimetabolites against 6-phosphogluconic acid, sedoheptulose and
erythrose, however, were free from this objection. In the early stages of HMP
pathway the carboxyl group of 6-phosphogluconic acid is liberated as carbon
dioxideleaving the rest ofthe moleculararrangementintact inribose-5-phosphate.
To be effective, the anti-metabohte has to have some functional resemblance to
its normalcounterpart; it is only then that the anti-metabolite can possibly com-
pete for active sites and block appropriate enzyme systems. The anti-metabolite
of 6-phosphogluconic acid therefore should have (i) a free carboxyl group at one
end and (ii) a free orphosphorylatedhydroxymethyl group or a carboxyl group at
the other end. Any dehberate departure then in the structural configuration of
central (CHOH)4 grouping of the 6-phosphogluconic acid molecule would result
in a substance having anti-metabolite properties. These considerations and also
the fact that gluconic acid is readily converted to a 5-membered y-lactones
structure (Fieser andFieser, 1960) prompted us to suggest thatfurans, tetrahydro-
furans and also thiophenes and tetrahydrothiophene derivatives of type (1),
JI), (111) and (IV) might inhibit malignant growth through interference of HMP.
It may not be out ofplace to mention here that 5-hydroxy methyl-2-furfuralde-
hyde (Heaton and Robinson, 1948) and 5-nitro-2-furfuraldehyde (Friedgood and
Green, 1950) have been shown to have potent cancer inhibiting properties.
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Ribose-5-phosphate is derived in the body not only by the oxidative decarbo-
xylation of 6-phosphogluconic acid ; it can also arise through the action of
transketolase and transaldolase enzymes. For effective inhibition of ribose-5-
phosphate formation therefore, it may be necessary simultaneously to interfere
with 6-phosphogluconic acid as well as with erythrose and/or sedoheptulose-7-
phosphate. A comprehensive programme ofsynthesis and testing of anti-cancer
properties of compounds of the types mentioned is in progress. The present
paper records the synthesis and anticancer properties of thiophene- 2 : 5-di-
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EXPERIMENTAL
Synthesis andproperties ofthiophene-2 : 5-dicarboxylic acid (TDA)
All the fourpossiblethiophene-dicarboxylic acids are known (Hartough, 1952
Sice, 1954 ; Kornfeld and Jones, 1954). Among the different methods available
for synthesis ofthiophene-2 : 5-dicarboxylic acid the two most convenient appear
to be the following :-
Method I.-Thiophene--*2: 5-dichloromethylthiophene-->2: 5-diacetoxymethy-
thiophene->Thiophene-2: 5-dicarboxylic acid (TDA).
Method 2.-Thiophene--->2: 5-diiodothiophene--*2: 5-dilithium derivative--->-
TDA.
In the present investigation thiophene-2: 5-dicarboxylic acid was prepared
by the second method. The yields by the first method were never more than 21
per cent or so, whereas by the second method the yield was 74 per cent. The
various stages in synthesis are as follows.
Preparation of 2 : 5-di-iodothio henefrom thiophene
Thiophene (16-8 g.; 0-2 mole) and benzene (20 c.c.) were taken in aglass stop-
pered flask, and iodine (105 g.; 0-42 mole) and yellow mercuric oxide (75 g.; 0-35
mole) were alternately added in small quantities during 2 hours with constant
shaking and occasional cooling to keep the temperature between 30-45'. The
yellow mercuric oxide turned crimson red because of its conversion to mercuric
iodide. Vigorous shaking is required and ifthe absorption ofiodine is incomplete
the mixture has to be shaken for an additional hour. The mixture was filtered
and the residue washed with benzene and ether. The ether-benzene filtrate was
washed several times with a 3 per cent solution of sodium thiosulfate tin it was
free from traces ofiodine. It was then washed with water and dried over calcium
chloride. On removal of the solvent 2, 5-diiodothiophene was obtained as a
brownish oil (55 g.). It was distilled at 116-17'/3-5 mm. The small amount of
monoidothiophene (2 g.) present was separated as a low boiling fraction. The
brownish oil (43 g., 64 per cent yield) gave a red-brown solid on cooling. Crystal- lization from alcohol gave white plates m.p. 40-41' (Minnis, 1943; m.p. 40-41').
Preparation ofphenyllithium (Evans and Allen, 1943)
A 250 c.c. three-neckedflask was fittedwith amercury-sealedstirrer, adropping funnel and a reflux condenser. Small pieces of lithium (21 g.; 0-3 gram atom)
(prepared by hammering the metal into a thin sheet and cutting it into small
thinstrips) and 50 c.c. dry ether wereplaced in it. A slow current ofnitrogen was
passed before the addition of lithium and ether and the subsequent reaction was
carried out under the atmosphere of nitrogen with constant stirring. Dry bromobenzeme (24 g.; 0-15 mole) in ether (20 c.c.) was added slowly during 20 to 30 minutes so that the mixture continued to reflux gently. The mixture
formed a gray precipitate of lithium bromide and was stirred for about II hour 2 till it attained room temperature. The contents of the flask were quickly filtered
through a cotton-plugged funnel in a 500 c.c. three-necked flask. During this
transfer and filtration the mixture was kept under nitrogen.550 SAHASRABUDHE, NERURKAR, NARURKAR, TILAK, BHAVSAR
Preparation of thiophene-2, 5-dicarboxylic acid (TDA) from 2, 5-diiodothiophene
(Campaigne and Foye, 1948)
To the above filtrate (stirred andkept underslightnitrogenpressure) a solutioll
of 2, 5-diiodothiophene (10-5 g.; 0-03 mole) in 50 c.c. ether was slowly added (10
minutes) when a white precipitate separated out. Stirring was continued for 10
minutes and the mixture poured into a beaker containing Dry Ice and allowed t',)
stand for 1-2 hours till all Dry Ice disappeared. The mixture was then acidified
with ice cold dilute hydrochloric acid (I : I ; 10 c.c.) and allowed to stand over-
night, when most ofthe ether evaporated off. The white solid (4-3 g.) was filtered
and washed with ice-cold water. It was then dissolved in dilute sodium bicar-
bonate, decolorized with Norit in the cold and filtered. TDA was thenprecipitated
by acidification when a white product (3-5 g.) was obtained. Some more product
(0-5 g.) was obtained from the aqueous filtrate, by extraction with ether. The
ether solution was again extracted with sodium bicarbonate solution and the
purification with Norit and precipitating the product by acidification was carried
out as indicated above. The crude acid (4-0 g.; yield 74 per cent) crystallised
from water in white needles.
M.P. 322-26' open capillary, shrinking at 318', effervescence at m.p.
(Found: C 41-8 per cent ; H 2-6, 8 18-5 per cent C6H404S requires C 41-8
H 2-3, 8 18-5 per cent).
Derivatives-2: 5-Dicarbethoxythiophene.
M.P. 50-51' (Friedgood and Green, 1950; m.p. 51-51').
(Found C 53-5; H 5-4; 8 14-5 ClOOH12 048 requires C 52-6; H 5-2 S 14-0
per cent).
Biological te-sting of TDA
Anticancer activity of TDA was tested on two transplantable tumours (1)
rapidly growing Yoshida sarcoma (ascites) in Wistar rats and (2) comparatively
slow growing solid fibrosarcoma in Swiss mice. Yoshida sarcoma was obtained
through the courtesy of Professor Druckerey (Freiburg). The solid fibrosarcoma
used in the present investigation was initially obtained by Waravdekar and
Ranadive (1957) from animals treated with 6: 12 dimethylbenzo (1: 2-b: 4: 5-b')
dithionapthene. This has since been maintained in Swiss mice through several
serial transplantations.
Influence on Yo-shida garcoma (a-scites)
0.5 ml. suspensions of Yoshida ascites sarcoma cells were injected intraperi-
toneally in 3-4 months old Wistar rats. Thiophene 2 : 5-dicarboxylic acid
(TDA) was disolved in 0-5 per cent NaHCO3 ('mg./0-5 ml.). Since the substance
is water soluble it was thought that it would be easily excreted out. Multiple
injections per day were therefore tried in an attempt to maintain adequate drug
concentration in the system. Secondly for sustained inhibition of tumour growth
the concentration of anti-metabolite in the body has to be more than that of its
normal counterpart. The dose of anti-metabolite therefore had to be determined
depending on the growth rate and the extent of tumour growth. In young
animals the growth of the Yoshida sarcoma is fairly rapid and results in the death
of all the transplanted animals by about the 4th or 5th day after transplantation.
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The influence ofTDA on slow tumourgrowth was also investigated bytransplant-
ing the tumour in 6-7 months old animals. Three doses were tried: I mg. once
aday, I mg. twice aday(daily dose 2mg.) and I mg. thrice aday(daily dose 3mg.).
Injections of TDA were evenly spaced during the day; the corresponding control
animals received only 0-5 ml. of the solvent (0-5 per cent NaHCO3 solution) intra-
peritoneally. Survival of treated and control animals was noted. The results
are given in Table 1.
TABLEI.-Influence of TDA on Survival of Yoshida Sarcoma
(Ascite8) Bearing Rats
Mean siirvival time
(in days)
Control* TDAtreatedt
6- 0 6- 5
4- 2 6- 0
4- 2 6- 0
9.5 30- 0
Treatment and
frequency of
injections
(1) I mg. TDA ONCE a day
.
(2) 1 mg. TDA TWICE a day
.
(3) 1 mg. TDA THRICE a day
(4) 1 mg. TDA TWICE a day
.
Total
daily dose
(mg.)
1
2
3
2
Age of
rats
(months)
3-3j
3
41
6-7t
* Control group received intraperitoneal injection of solvent (O
- 5 per cent NaHC03) only. t TDA was dissolved in 0
- 5 per cent NaHCO3 (concentration 2 mg./I ml.) and administered
intraperitoneaUy.
$ The growth of tumour in older animals is comparatively slow.
Influence on solidflbrosarcoma
In the case ofsolid fibrosarcoma the tumour mass was cut into fine pieces with
scissors and a homogeneous suspension was prepared in normal saline. 0-5 ml.
of the suspension was injected subcutaneously through an 18 gauge needle in
each of the Swiss mice. Since the cell count of each inoculum could not betaken,
the tumour was allowed to grow in all animals for 7 to 8-days before the treat-
ment was started. On completion of this period animals having comparable
tumour sizes (by visual observation) were selected and divided into two groups. The experimental group wasinjected with TDA dissolved in 0-5 per centNaHCO3,
while the control group received the injections of the solvent (0-5 per cent
NaHC03)- In these experiments also the influence of one injection and multiple
injections per day was investigated. After 10 to 15 days of treatment the
animals were killed and the weights of the tumours determined. The results are
given in Tables 11 and III and in Fig. I and 2.
TABLE II.-Influence of one Injection Per Day of TDA on the
Growth ofTransplanted Fibrosarcoma in Swiss Mice
Day of
Frequency of starting Period of Average weight administra- treatment after treatment of tumours and
Daily dose tion transplantation (days) range
Control* . 0
- 5 ml. of 0 5%
. Once daily
. Ist 17 2-8 g. NaHCO3 only (1
- 56-4
- 65 g.)
TDA- . lmg.TDAinO-5
. 99 9 9
treatedt ml. of 0-5%
NaHCO3 SO'Ut-
tion
Ist 17 2 I rrg.
(I
- 59-2 57 g.)
* Control group was injected with the solvent (O
- 5 per cent NaHC03) only. t TDA was dissolved in 0
- 5 per cent NaHCO3 (concentration 2 mg. TDA/ml.).552 SAHASRABUDHE, NERURKAR, NARURKAR, TILAK, BHAVSAR
TABLIF, III.-Influence ofMultiple Injections per day of TDA on
the Growth ofTransplanted Fibrosarcoma in Swiss MiCe
Tirne of
starting
Frequency of treatment a-fter Period of Average weight
administra- transplantation treatment of tumours and
Daily dose tion (days) (days) range
Control* 0 5 ml. of 0
- 5% Twice daily 10 15 8-2 g.
NaHCO3 only (6
- 36-9
- 18 g.)
TDA- 2 mg. TDA dis- I mg. twice 10 15 3-16 g.
treatedt solved in 0
- 5% daily (I
- 79-3
- 90 g.)
NaHCO3 801U_
tion
Tumour was aRowed tG grow for 10 days. Then the animals having uniform tumour sizes were
divided into control and experimental groups.
* The control group was injected with corresponding volume of the solvent, i.e. 0
- 5 per cent
NaHCO,, solution.
t TDA was dissolved in 0
- 5 per cent NaHCO.. Every time I mg. dissolved in 0
- 5 ml. of 0
- 5
per cent NaHCO3 was injected.
In vitro studies on interference o HMP f
In addition to the in vivo screening of antitumour activity it was necessary
to ascertain whether TDA really interfered with the HMP pathway. This has
beeninvestigated inin vitro studiesbyincubating the tumour tissue with glucose-
1_14C andglucose-6-14C, with andwithoutthepresenceofTDA. Six toeight weeks
old Swiss miceweighing between 20 and 25 g. were used. Solid fibrosarcoma was
transplanted subcutaneously. Tumours were dissected out three weeks after
transplantation and homogenised in Potter Elvehjem glass homogeniser in 6
volumes of ice cold medium containing 0-133 m phosphate buffer (pH 7-4). Ali-
quots representing 80 mg. of tumour tissue were added to chilled Warburg
vessels. The incubation medium consisted of the following substances expressed
in their final concentrations (Wenner and Weinhouse, 1956):-Potassium fu-
marate 7 X 10-5M ; cytochrome C 4 x 10-1m ; DPN 2 x 10-3m ; phosphate
buffer (pH 7-4) 6-0 X 10-3m; MgSO4 3 X 10-3M; KCI 1-4 x 10-1m; glucose
0-020 m and glucose-1_14C or glucose-6-14C (as the case may be) equivalent to
6-42 X 104 CpM. 1 mg. of thiophene 2, 5-dicarboxylic acid dissolved in 0-5 c.c.
of 0-5 per cent NaHC03was added to the medium. A rolled filter paper soaked
in 0-2 ml. 10 N NaOH was placed in the central well ofWarburg flasks to absorb
the C02 released. 0-3 ml. 50 per cent trichloroacetic acid was placed in the side
arm. The flasks were attached to manometers and the assembly shaken for 4
hours. At the end of this period, trichloroacetic acid was tipped in the reaction
vessels to stop the reaction and to li'berate C02 from the incubation medium.
The flasks were shaken for an additional period of 60 minutes to allow complete
absorption of C02 by the alkali. The manometers were then detached and the
EXPLANATION OF PLATE.
FIG. I.-Inhibition of growth of transplantable fibrosarcoma with TDA treatment. Dose
2 mg./day. Treatment started 10 days after transplantation and continued for 15 days. Left hand-treated with TDA; right hand-control.
FIG. 2.-The same animal as in Fig. 1. With the tumour exposed. Note the inhibition of
growth in the TDA treated animal. Left hand-treated with TDA; right hand-control.Vol. XIV, No. 3. BRiTISH JO-UIRNAL OF CANCER.
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1. filter papers and the rinsings of the central weR with 0-5 per cent NaHC03were
carefully transferred to test tubes and made up to a known volume. Aliquots
of this were taken for plating and counting with a thin window G.M. counter
(1-5-2 Mg./CM2)
. The results are given in Table IV.
TABLE IV.-Influence of Thiophene 2, 5-Dicarboxylic acid on the Liberation of
Radioactive 14('!O 2 from Gluco8e-1-14C Glucose-6-14C Sub,3trate8 by Tumomi-
Ti8-sue
Radioactive 14CO2
Substrate Additions given out
Glucose I_14C Nil I-27
Glucose-I_14C Thiophene-2,5-dicarboxylic acid 71
Glucose-(j_14C Nil 45
Glucose-6_14C Thiophene-2,5-dicarboxylic acid 26
RESULTS AND DISCIITSSION
It will be seen from Table I that there was not much difference in the survival
of the control and treated animals when only single injection of TDA (I mg.)
was given every day. When the frequency of injections and daily dose was
increased, the TDA treated animals survived longer. NA'hen the dose and fre-
quency of daily injections were increased and at the same time the growth of the
tumour was slowed down (as in old animals) the results were striking. In this
group the treated animals survived up to 30 days whereas the control animals
died by the 12th day after transplantation.
Similar results were obtained with the solid fibrosarcoma in Swiss mice.
When the daily dose was I mg. once only theweights ofthe tumours in the control
untreated animals were not markedly different from those of the treated animals.
But when the frequency and the daily dose was increased, significant inhibition
of tumour growth was evident in the TDA treated animals. Thus whereas the
mean weight of the tumour in the control animals was 8-0 g. that of the treated
groups was 3-0 g. This is clearly seen in the photographs of the treated and
untreated animals (Fig. I and 2).
In the in vitro studies with glucose-1_14C and glucose-6-14C it was seen that
liberation of radioactive 14CO 2 from glucose-1_14C was diminished in presence of
TDA suggesting that the HMP was probably inhibited by the presence of TDA.
It will be noticed that in the presence of TDA the liberation of radioactive 14CO2
from glucose-6-14C substrate was also diminished. This is due to the fact that in
tumour tissue a portion of trioses is obtained via the HMP pathway. If this is
so then the diminution in the evolution of radioactive C02 when glucose-6-14C
is used is to be expected. In vitro studies thus seem to justify the premise that
TDA or similar substances would inhibit the HMP pathway and thus bring about
inhibition of tumour growth.
SUMMARY
Inhibition of tumour growth with anti-metabolites ofhexose-mono-phosphate (HMP) intermediates has been attempted. Thiophene 2 : 5-dicarboxylic acid
(TDA) has been synthesized and its tumour inhibiting properties have been
investigated on Yoshida (ascites) sarcoma in rats and on transplantable solid554 SAHASRABUDHE, NERURKAR, NARURKAR, TILAK, BHAVSAR
fibrosarcoma in Swiss mice. The survival of Yoshida sarcoma bearing rats was
increased with TDA treatment, whereas with the solid fibrosarcoma a significant
inhibition of tumour growth was evident. In vitro studies carried out with
glucose-1-14C and glucose-6-14C suggest that TDA interferes with the HMP
pathway.
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